TABLE 3.
NTR cumulative incidence and survival according to pre‐ablative NTR model
| Low risk (n = 08; 50.7%) HCC‐naïve and AFP < 100 ng/ml | Intermediate risk (n = 92; 43.2%) Prior HCC and AFP < 100 ng/ml | High risk (n = 13; 6.1%) AFP ≥ 100 ng/ml | |
|---|---|---|---|
| AFP model | |||
| NTR (%) | |||
| Overall b | 9.3% | 22.8% | 61.5% |
| At first recurrence b | 2.8% | 15.2% | 38.5% |
| at 1 year | 4.1% | 10.7% | 35.3% |
| at 2 years | 7.9% | 19.9% | 57.5% |
| at 3 years | 9.1% | 22.5% | 62.6% |
| at 4 years | 10.7% | 26.2% | 68.9% |
| Time to NTR a , b (median [IQR]) | 16.8 months (6.7–40.4) | 12.8 months (10.3–21.1) | 5.4 months (4–13.6) |
| Milan criteria | |||
| NTR (%) | |||
| Overall b | 12% | 31.5% | 53.8% |
| At first recurrence b | 3.7% | 25% | 38.5% |
| at 1 year | 6.1% | 17.4% | 32.6% |
| at 2 years | 10.4% | 28.2% | 49.7% |
| at 3 years | 12% | 32% | 55.1% |
| at 4 years | 13.7% | 36% | 60.4% |
| Time to NTR a , b (median [IQR]) | 15.2 months (10.7–28.1) | 10.5 months (8.4–15.8) | 5.6 months (3.5–14.7) |
| Survival | |||
| RFS (median [95% CI]) | 43.4 months (23.6–50.2) | 14.5 months (8.6–18.3) | 4.6 months (2.2–23.5) |
| OS (median [95% CI]) | NR | NR | 19.1 months (10.3–NR) |
Abbreviations: NR, not reached; OS, overall survival; RFS, recurrence‐free survival.
a
Among patients presenting NTR.
b
Indicates significant differences among the three risk categories (p < 0.001).